Unpacking the Latest Options Trading Trends in Eli Lilly
Unpacking the Latest Options Trading Trends in Eli Lilly
Whales with a lot of money to spend have taken a noticeably bearish stance on Eli Lilly.
那些擁有大量資金的鯨魚已經顯著看淡了Eli Lilly。
Looking at options history for Eli Lilly (NYSE:LLY) we detected 30 trades.
查看Eli Lilly（紐交所：LLY）的期權歷史，我們發現了30筆交易。
If we consider the specifics of each trade, it is accurate to state that 30% of the investors opened trades with bullish expectations and 43% with bearish.
如果我們考慮每筆交易的具體細節，可以準確地說有30%的投資者看漲，43%的投資者看淡。
From the overall spotted trades, 4 are puts, for a total amount of $423,567 and 26, calls, for a total amount of $4,363,478.
從整體交易中，有4筆看跌期權，總金額爲423,567美元，有26筆看漲期權，總金額爲4,363,478美元。
Projected Price Targets
預計價格目標
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $700.0 to $1100.0 for Eli Lilly during the past quarter.
分析這些合約的成交量和持倉量，看起來大戶在過去的季度裏將Eli Lilly的價格區間定在700.0到1100.0美元之間。
Insights into Volume & Open Interest
成交量和持倉量分析
In terms of liquidity and interest, the mean open interest for Eli Lilly options trades today is 498.6 with a total volume of 1,460.00.
就流動性和興趣而言，Eli Lilly期權交易的平均持倉量爲498.6，總成交量爲1,460.00。
In the following chart, we are able to follow the development of volume and open interest of call and put options for Eli Lilly's big money trades within a strike price range of $700.0 to $1100.0 over the last 30 days.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Eli Lilly's big money trades within a strike price range of $700.0 to $1100.0 over the last 30 days.
Eli Lilly Call and Put Volume: 30-Day Overview
Eli Lilly Call and Put Volume: 30-Day Overview
Significant Options Trades Detected:
檢測到重大期權交易：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | CALL | SWEEP | BEARISH | 11/15/24 | $223.4 | $217.55 | $220.0 | $700.00 | $2.2M | 836 | 300 |
| LLY | CALL | SWEEP | NEUTRAL | 01/17/25 | $81.9 | $80.95 | $81.9 | $900.00 | $311.3K | 1.8K | 46 |
| LLY | PUT | SWEEP | BULLISH | 10/18/24 | $28.3 | $25.0 | $25.0 | $900.00 | $300.4K | 883 | 2 |
| LLY | CALL | SWEEP | NEUTRAL | 01/17/25 | $119.15 | $115.4 | $119.15 | $840.00 | $273.9K | 459 | 7 |
| LLY | CALL | TRADE | BEARISH | 11/15/24 | $51.65 | $48.8 | $48.8 | $930.00 | $239.1K | 535 | 100 |
| 標的 | 看跌/看漲 | 交易類型 | 情緒 | 到期日 | 賣盤 | 買盤 | 價格 | 執行價格 | 總交易價格 | 未平倉合約數量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | 看漲 | SWEEP | 看淡 | 11/15/24 | 223.4美元 | 217.55美元 | 220.0美元 | $700.00 | $2.2M | 836 | 300 |
| LLY | 看漲 | SWEEP | 中立 | 01/17/25 | $81.9 | 80.95美元 | $81.9 | $900.00 | 311.3K美元 | 1.8K | 46 |
| LLY | 看跌 | SWEEP | 看好 | 10/18/24 | $28.3 | $25.0 | $25.0 | $900.00 | 300.4千美元 | 883 | 2 |
| LLY | 看漲 | SWEEP | 中立 | 01/17/25 | $119.15 | $115.4 | $119.15 | $840.00 | $273.9K | 459 | 7 |
| LLY | 看漲 | 交易 | 看淡 | 11/15/24 | $51.65 | 48.8美元 | 48.8美元 | $930.00 | 成交量$239.1K | 535 | 100 |
About Eli Lilly
關於Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Eli Lilly是一家專注於神經科學，心臟代謝，癌症和免疫學的藥物公司。Lilly的主要產品包括用於治療癌症的Verzenio；用於心臟代謝的Mounjaro，Zepbound，Jardiance，Trulicity，Humalog和Humulin；以及用於免疫學的Taltz和Olumiant。
Following our analysis of the options activities associated with Eli Lilly, we pivot to a closer look at the company's own performance.
在對Eli Lilly的期權活動進行分析後，我們轉向更仔細地觀察該公司的業績。
Present Market Standing of Eli Lilly
Eli Lilly的當前市場地位
- Currently trading with a volume of 365,615, the LLY's price is down by -1.32%, now at $911.36.
- RSI readings suggest the stock is currently may be approaching oversold.
- Anticipated earnings release is in 44 days.
- 目前交易量爲365,615，LLY的價格下跌了-1.32%，目前爲$911.36。
- RSI讀數表明該股票目前可能接近超賣狀態。
- 預期四十四天後公佈收益。
Professional Analyst Ratings for Eli Lilly
Eli Lilly的專業分析師評級
5 market experts have recently issued ratings for this stock, with a consensus target price of $1007.2.
5名市場專家最近對這隻股票發表了評級，共識目標價爲$1007.2。
- In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $885.
- Reflecting concerns, an analyst from Citigroup lowers its rating to Buy with a new price target of $1060.
- Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Eli Lilly with a target price of $1100.
- In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $885.
- An analyst from Morgan Stanley has revised its rating downward to Overweight, adjusting the price target to $1106.
- 爲了謹慎起見，Cantor Fitzgerald的分析師將其評級下調爲超重，設定了885美元的價格目標。
- 反映擔憂，花旗集團的一位分析師將其評級降至買入，新的目標價爲$1060。
- 摩根士丹利的一位分析師在對Eli Lilly的評估中保持超配評級，目標價爲$1100。
- 爲了謹慎起見，Cantor Fitzgerald的分析師將其評級下調爲超重，設定了885美元的價格目標。
- 摩根士丹利的一名分析師已將其評級下調爲增持，將目標價調整爲1106美元。
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Eli Lilly with Benzinga Pro for real-time alerts.
交易期權既涉及更大的風險，也提供了更高的利潤潛力。精明的交易員通過持續的教育、戰略性的交易調整、利用各種指標並保持對市場動態的關注來降低這些風險。通過Benzinga Pro隨時獲得Eli Lilly最新的期權交易提醒。
譯文內容由第三人軟體翻譯。